Might the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle and reconsider the “all applicants” approach?

Publikation: AndetUdgivelser på nettet - Net-publikationFormidling

The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the EPO. Ultimately, some of the issues might still be referred to the Enlarged Board of Appeal. However, this might require a significant amount of legal and rhetorical agility.
Publikationsdatojul. 2018
UdgiverHarvard Law School's Bill of Health blog
StatusUdgivet - jul. 2018

ID: 199590381